Mesothelin (Msln) is a rational target for ovarian cancer immunotherapy [2] - it contributes to the malignant and invasive phenotype in these tumors and has limited expression in healthy cells [3,4,5]. This evidence concerns the gene MSLN and ovarian carcinoma.